| CI-1033 |
| N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide |
| (CAS 267243-28-7) |
 |
| Description： |
Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM).
Drug Interactions: Canertinib has been reported as a substrate for OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions.[3] Also, canertinib is not an inhibitor of OATP-1B1 or OATP-1B3 transporter.
|
| Product No. |
KT00272 |
| Product Name |
CI-1033 |
| Synonyms |
Canertinib; PD183805 |
| Formal Name |
N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide |
| CAS Number |
267243-28-7 |
| Molecular Formula |
C24H25ClFN5O3 |
| Formula Weight |
485.94 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
AR-A014418
AZD1080
AZD2858
BIO
CHIR-98014
GSK-3 inhibitor 1
IM-12
LY2090314
SB 216763
SB 415286
TDZD-8
|
|
